All Updates

All Updates

icon
Filter
Partnerships
PrecisionLife and Nxera Pharma expand partnership to target auto-immune disorders drug discovery
AI Drug Discovery
May 30, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Jun 20, 2024
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Jun 20, 2024
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Jun 20, 2024
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Jun 20, 2024
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Jun 20, 2024
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Jun 20, 2024
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Jun 20, 2024
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Jun 20, 2024
AI Drug Discovery

AI Drug Discovery

May 30, 2024

PrecisionLife and Nxera Pharma expand partnership to target auto-immune disorders drug discovery

Partnerships

  • PrecisionLife and Nxera Pharma have expanded their collaborative partnership to potentially discover new drug targets for treating auto-immune disorders. The collaboration was announced as an extension of the companies' existing partnership, established in 2022.

  • The partnership aims to establish precision-targeted therapies for auto-immune disorders. PrecisionLife's disease insights and stratification biomarkers will be used to identify patient subgroups, enabling Nxera to determine suitable drug targets accurately. This collaboration aims to leverage the combined strengths of both companies to develop effective treatments for complex diseases in the future.

  • UK-based PrecisionLife specializes in generating biological insights into complex chronic diseases. Leveraging its AI-led Innovation Engine and combinatorial analytics, the company aims to accelerate drug development and personalize healthcare by identifying disease mechanisms relevant to specific patients. The company’s services include discovering novel drug targets, enriching clinical trials, and creating personalized diagnostics.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.